Engineered interleukin-2 receptor

Engineered interleukin-2 receptors are not natural receptors but refer to a diverse category of synthetic or modified receptor or ligand-receptor systems inspired by the human IL-2/IL-2 receptor complex. The native IL-2 receptor is a heterotrimeric cytokine receptor (composed of IL-2Rα/CD25, IL-2Rβ/CD122, and IL-2Rγ/CD132) that mediates the immunostimulatory and immunoregulatory effects of interleukin-2, a key cytokine for T cell growth, activation, and immune homeostasis[1]. Engineered forms leverage protein engineering (e.g., altered amino acid sequences, PEGylation, antibody fusion, etc.) to reprogram IL-2's receptor binding preferences or signaling properties, aiming to selectively activate beneficial immune cell populations (such as CD8+ T cells for cancer or Tregs for autoimmune diseases) while minimizing toxicity and adverse events seen with natural IL-2 signaling, such as vascular leak syndrome and cytokine release[2][5][6]. These innovations have produced a new generation of biologics (e.g., THOR-707, SAR-444245, PT101, NKTR-358) with enhanced selectivity, improved pharmacokinetics, and novel therapeutic potential for cancer, autoimmunity, and other immune-mediated disorders[4][5][6].

Other names

Engineered IL-2RSynthetic interleukin-2 receptorIL-2 receptor chimeraTHOR-707SAR-444245Interleukin-2 receptorCD25/CD122/CD132

Selective activation of effector CD8+ T cells and NK cells by engineered IL-2 analogs that avoid regulatory T cell (Treg) stimulation Immunomodulation: Treg expansion (using Treg-biased engineered IL-2 ligands) Partial agonism or antagonism (receptor clamps, superkines, muteins blocking native receptor function) Prolonged half-life and tissue targeting through PEGylation or Fc-fusion Reduced vascular leak and cytokine storm by minimizing engagement of certain receptor subunits